The clinical significance of brain natriuretic peptide in patients with chronic obstructive pulmonary disease

Cover Page

Cite item

Full Text

Abstract

The main causes of dyspnea in patients of the older age group are chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF). These diseases share common risk factors, similarities and common clinical pathogenesis. In recent years, important principles of diagnosis of CHF consist of using a tool and laboratory (BNP and NT-proBNP) markers. Currently, it is securely and strictly evidence-based, that the detection of elevated concentrations of BNP and NT-proBNP indicates the presence of the patient's myocardial dysfunction and heart failure. The article presents data on the role and significance of natriuretic peptides in the diagnosis of the presence and severity of heart failure in patients with COPD.

About the authors

N. A Karoli

ГБОУ ВПО Саратовский государственный медицинский университет им. В.И.Разумовского Минздрава России

д-р мед.наук, проф. каф. госпитальной терапии лечебного факультета

A. V Borodkin

ГБОУ ВПО Саратовский государственный медицинский университет им. В.И.Разумовского Минздрава России

аспирант каф. госпитальной терапии лечебного факультета

M. A Kurnosova

ГБУЗ Областная клиническая больница, Саратов

врач-кардиолог

A. P Rebrov

ГБОУ ВПО Саратовский государственный медицинский университет им. В.И.Разумовского Минздрава России

д-р мед.наук, проф., зав. каф. госпитальной терапии лечебного факультета

References

  1. Egred M, Shaw S, Mohammad P et al. Under - use of beta - blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. Q J Med 2005; 98: 493-7.
  2. De Miguel Díez J, Chancafe Morgan J, Jiménez García R. The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis 2013; 8: 305-12.
  3. Hawkins N.M, Petrie M.C, Jhund P.S et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009; 11 (2): 130-9.
  4. Le Jemtel T.H, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007; 49 (2): 171-80.
  5. Nielsen L.S, Svanegaard J, Wiggers P, Egeblad H. The yield of a diagnostic hospital dyspnoe clinic for the primary health care section. J Intern Med 2001; 250: 422-8.
  6. Сапрыгин Д.Б., Мошина В.А. Клиническое применение мозгового натрийуретического пептида (аминотерминального фрагмента) - NT-proBNP в кардиологической практике. Уральский медицинский журнал. 2007; 7: 95-102.
  7. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 81: 1-94.
  8. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990; 168: 863-70.
  9. Omland T. Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. Crit Care Med 2008; 36 (1 Suppl.): S17-27.
  10. Jelic S, Le Jemtel T. Diagnostic Usefulness of B-Type Natriuretic Peptide and Functional Consequences of Muscle Alterations in COPD and Chronic Heart Failure. Chest 2006; 130 (4): 1220-30.
  11. Hildebrandt P, Collinson P.O, Doughty R.N et al. Age - dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut - point for ruling out suspected systolic dysfunction in primary care. See comment in PubMed Commons below. Eur Heart J 2010; 31 (15): 1881-9.
  12. Tschöpe C, Kasner M, Westermann D, Gaub R et al. The role of NT- proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 2005; 26 (21): 2277-84.
  13. Iwanaga Y, Nishi I, Furuichi S, Noguchi T et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006; 47 (4): 742-8.
  14. O’Donoghue M, Kenney P, Oestreicher E, Anwaruddin S et al. Use - fulness of aminoterminal pro - brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study). Am J Cardiol 2007; 100 (9): 1336-40.
  15. Abroug F, Ouanes-Besbes L. Detection of acute heart failure in chronic obstructive pulmonary disease patients: role of B-type natriuretic peptide. Curr Opin Crit Care 2008; 14 (3): 340-7.
  16. Nishimura K, Nishimura T, Onishi K et al. Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9: 155-62.
  17. Lang C.C, Coutie W.J, Struthers A.D et al. Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. Clin Sci 1992; 83: 529-33.
  18. Bozkanat E, Tozkoparan E, Baysan O et al. The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease. J Int Med Res 2005; 33 (5): 537-44.
  19. Inoue Y, Kawayama T, Iwanaga T, Aizawa H. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. See comment in PubMed Commons below. Intern Med 2009; 48 (7): 503-12.
  20. Tung R.H.Jr., Camargo C.A, Krauser D et al. Amino - terminal pro - brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann Emerg Med 2006; 48 (1): 66-74.
  21. Тертичная С.П., Паршукова В.Н. Мозговой натрийуретический пептид в диагностике сердечной недостаточности у больных хронической обструктивной болезнью легких. Клин. практика. 2011; 4: 29-34.
  22. Gariani K, Delabays A, Perneger T.V et al. Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease. Swiss Med Wkly 2011; 141: w13298.
  23. Rutten F.H, Moons K.G, Cramer M.J et al. Recognizing heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 2005; 331 (7529): 1379-86.
  24. Morrison L.K, Harrison A, Krishnaswamy P et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39 (2): 202-9.
  25. Laratta C.R, Van Eeden S. Acute exacerbation of chronic obstructive pulmonary disease: cardiovascular links. Biomed Res Int 2014: Article ID 528789.
  26. Wang Q.P, Cao X.Z, Wang X.D et al. Utility of NT-proBNP for identifying LV failure in patients with acute exacerbation of chronic bronchitis. PLoS One 2013; 8 (1): e52553.
  27. Macchia A, Rodriguez Moncalvo J.J, Kleinert M et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J 2012; 39 (1): 51-8.
  28. Баймаканова Г.Е., Авдеев С.Н. Диагностическая и прогностическая значимость концевого N-отрезка мозгового натрийуретического пептида (Nt - proBNP) при обострении хронической обструктивной болезни легких. Пульмонология. 2011; 6: 80-86.
  29. Bando M, Ishii Y, Sugiyama Y, Kitamura S. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med 1999; 93 (7): 507-14.
  30. Boschetto P, Fucili A, Stendardo M et al. Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure. Respirology 2013; 18 (1): 125-30.
  31. Agarwal S.K, Heiss G, Barr R.G et al. Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail 2012; 14 (4): 414-22.
  32. Inoue Y, Kawayama T, Iwanaga T, Aizawa H. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med 2009; 48 (7): 503-12.
  33. Stolz D, Breidthardt T, Christ-Crain M et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008; 133 (5): 1088-94.
  34. Hoiseth A.D, Omland T, Hagve T.A et al. NT-proBNP independently predicts long term mortality after acute exacerbation of COPD - a prospective cohort study. Respir Res 2012; 13: 97.
  35. Mueller C, Laule-Kilian K, Frana B et al. Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. Am Heart J 2006; 151 (2): 471-7.

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies